Lastly, the prediction of the pathologic response to neoadjuvant chemotherapy was investigated by Bitencourt et al. They demonstrated, with a diagnostic accuracy of 83.9% (52/62), that MRI-based clinical and radiomic features coupled with machine learning were able to predict pathologic response after neoadjuvant chemotherapy in HER2 overexpressing breast cancer patients [37]. Here, ERBB2 is linked to breast carcinoma.